TCT 2022

Randomized, Double-Blind Trial of Routine Early Treatment with PCSK-9 inhibitor in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

C. Michael Gibson speaks with Shamir Mehta discuss LDL reduction with PCSK-9 inhibitors among patients with STEMI.

We Recommend